Press Releases

05.10.2017

SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY

05.09.2017

FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer

05.09.2017

FDA Grants Second Approval for BAVENCIO® (avelumab)

05.09.2017

New Smartphone App May Enable Lupus Patients to Report Symptoms More Easily and Accurately

05.08.2017

Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the World’s Poorest Countries

05.03.2017

Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine

05.03.2017

Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis

05.02.2017

Pfizer Reports First-Quarter 2017 Results

04.27.2017

Pfizer Hosts Annual Meeting of Shareholders

04.27.2017

Insphero Announces Agreement With Pfizer To Develop Novel Assays For Predicting Drug-Induced Liver Injury

04.27.2017

Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

04.25.2017

Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease